Our Technology

Cold plasma.
No chemicals.
No heat. No resistance.

Aceso Plasma is a handheld, portable device that converts ambient air into oxygen plasma — generating Reactive Oxygen Species (ROS) that disinfect wounds, accelerate healing, and support hemostasis without thermal damage, chemicals, or the risk of antibiotic resistance.

O₂
Molecular oxygen
Plasma
O⁻
Oxygen plasma ions
ROS
ROS
Reactive oxygen species
No oxygen tanks required No harmful UV emissions AC or DC powered Below 55°C — no thermal damage Zero antibiotic resistance risk
Aceso Plasma handheld device — converts ambient air into oxygen plasma
Investigational device
Pending FDA clearance · Not for sale
Important: Aceso Plasma is an investigational device currently pending FDA clearance. This device is not approved or available for clinical use or sale.
The science

How it works

Aceso Plasma converts ambient air into Reactive Oxygen Species through a six-step oxidation process that destroys pathogens at a molecular level — without chemicals, heat, or the risk of resistance.

Aceso Plasma ROS mechanism of action — six-step oxidation cycle
1

Oxygen ion formation

Oxygen ions are created within the plasma as ambient air passes through the device.

4

Oxidation reaction on cell wall proteins

ROS induce an oxidation reaction across all cell wall proteins simultaneously — the key mechanism that prevents resistance from developing.

2

ROS generation

Oxygen ions transform into Reactive Oxygen Species — highly energized molecules capable of destroying microbial cell walls.

5

Protein denaturation

Proteins denature due to oxidation, compromising the structural integrity of the microorganism.

3

ROS interaction with microorganisms

ROS initiate decontamination of bacteria, fungi, and molds on contact.

6

Cell wall perforation

A hole is left in the cell wall, leading to apoptosis — complete destruction of the pathogen.

Key advantage

Resistance-free
by design

Unlike antibiotics and conventional antimicrobials, microorganisms cannot develop resistance to Aceso Plasma. Because the ROS oxidation reaction interacts with all proteins simultaneously — rather than targeting a single biochemical pathway — there is no mechanism through which bacteria can adapt or evolve resistance.

No resistance pathway — all cell wall proteins are targeted simultaneously, leaving no single mutation point for adaptation.

Effective against ESKAPE pathogens — demonstrated efficacy against antibiotic-resistant strains in investigational studies at MedStar Georgetown Research Institute.

Accelerates healing — by reducing bioburden, Aceso allows the body to bypass the inflammatory stage and move faster through the wound healing cascade.

Technology pillars

What makes Aceso Plasma different

Five core technology advantages that set Aceso Plasma apart from conventional wound care and disinfection approaches — in both clinical and field environments.

Precision ROS generation

Converts molecular oxygen (O₂) into oxygen plasma ions (O⁻), creating highly reactive oxygen species that destroy pathogens at a molecular level — without affecting surrounding healthy tissue.

Cold plasma technology

Operates below 55°C — safely treating delicate tissues with no risk of thermal damage. Delivers the antimicrobial power of plasma without the harmful side effects associated with heat-based or chemical approaches.

No tanks. No chemicals.

Uses ambient air as its only input. No external gas tanks, no chemical agents, no harmful UV emissions. Environmentally clean and logistically simple — critical for austere field deployment.

Portable power

Powered by AC or DC, the device operates across clinical settings and austere field environments without sacrificing output. Lightweight, hand-portable, and ready to deploy where it's needed most.

Versatile applications

Adaptable across wound healing, disinfection, hemostasis, pain management, and equipment decontamination — in clinical, surgical, dermatological, and military field settings.

Disinfection capability

Broad-spectrum efficacy

In investigational studies conducted at MedStar Georgetown Research Institute, Aceso Cold Plasma demonstrated antimicrobial efficacy comparable to Povidone Iodine across a broad spectrum of pathogens — including antibiotic-resistant ESKAPE organisms.

Conventional disinfectants eliminate bacteria — but many also damage healthy host cells, impede wound healing, and face growing resistance from drug-resistant strains. Aceso Cold Plasma takes a fundamentally different approach.

By generating Reactive Oxygen Species that interact with all microbial proteins simultaneously, Aceso Plasma destroys pathogens without a mechanism through which resistance can develop. The same treatment that kills bacteria also supports — rather than hinders — the body's natural healing process.

Investigational studies conducted at MedStar Georgetown Research Institute demonstrated efficacy across gram-positive, gram-negative, anaerobic, and microaerophilic bacterial species, as well as yeast isolates including Candida auris — all pathogens of significant clinical concern.

14+
Pathogen species tested in investigational studies
0
Negative effects on healthy host cells observed
45s
Treatment time demonstrating high-efficacy results
3
Independent research institutions validating efficacy

Broad-spectrum pathogen coverage

Effective against gram-positive, gram-negative, anaerobic, and microaerophilic species, as well as yeast isolates including Candida auris — covering the full spectrum of wound-relevant pathogens.

Effective against drug-resistant strains

Demonstrated efficacy against antibiotic-resistant ESKAPE pathogens — organisms where conventional antimicrobial agents are increasingly ineffective. Resistance cannot develop against the ROS oxidation mechanism.

Does not impede healing

Unlike many chemical disinfectants — including silver sulfadiazine and povidone iodine — Aceso Cold Plasma demonstrated no negative impact on healthy host cells or wound healing trajectory in investigational studies.

Scalable beyond wound care

The same ROS technology adapts to decontamination of medical and tactical equipment, surfaces, air, and water — giving it utility well beyond direct wound application in both clinical and field settings.

"

Because ACP was effective against some antibiotic resistant species, ACP may be effective in some settings where other antimicrobial agents will not be. This data suggests that ACP has unique clinical relevancy as a hand-held wound cleansing agent and decontamination device.

JS

Dr. Jeffrey Shupp, MD

MedStar Health Research Institute — Investigational Study Conclusion

Investigational notice: All data referenced on this page reflects findings from pre-clinical and investigational research studies. Aceso Plasma is pending FDA clearance and is not currently approved or available for clinical use. Study conclusions are drawn from SBIR Phase II-funded research conducted at MedStar Georgetown Research Institute, Wake Forest Institute of Regenerative Medicine, and the US Army CCDC CBC.

Learn More